Home » Stocks » Novocure

Novocure Limited (NVCR)

Stock Price: $123.77 USD -1.27 (-1.02%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $120.15 -3.62 (-2.93%) Oct 23, 7:50 PM

Stock Price Chart

Key Info

Market Cap 12.51B
Revenue (ttm) 409.05M
Net Income (ttm) 11.80M
Shares Out 101.09M
EPS (ttm) 0.11
PE Ratio 1,125.18
Forward PE 312.50
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $123.77
Previous Close $125.04
Change ($) -1.27
Change (%) -1.02%
Day's Open 125.59
Day's Range 121.73 - 127.48
Day's Volume 736,625
52-Week Range 53.40 - 140.89

More Stats

Market Cap 12.51B
Enterprise Value 12.33B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 101.09M
Float 83.59M
EPS (basic) 0.13
EPS (diluted) 0.11
FCF / Share 0.24
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.09%
FCF Yield 0.19%
Payout Ratio n/a
Shares Short 5.33M
Short Ratio 3.80
Short % of Float 6.38%
Beta 1.40
PE Ratio 1,125.18
Forward PE 312.50
P/FCF Ratio 513.27
PS Ratio 30.59
PB Ratio 47.20
Revenue 409.05M
Operating Income 7.30M
Net Income 11.80M
Free Cash Flow 24.38M
Net Cash 184.34M
Net Cash / Share 1.82
Gross Margin 64.31%
Operating Margin 1.78%
Profit Margin 2.90%
FCF Margin 5.96%
ROA 1.02%
ROE 5.53%
ROIC 1.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 3
Overweight 0
Hold 5
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$108.00*
(-12.74% downside)
Low
75.0
Current: $123.77
High
200.0
Target: 108.00
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue35124817782.8933.0915.4910.36
Revenue Growth41.62%40.13%113.57%150.52%113.6%49.53%-
Gross Profit26316812136.6112.485.453.35
Operating Income-0.91-33.67-39.33-115-104-80.16-64.46
Net Income-7.23-63.56-61.66-132-112-80.68-77.37
Shares Outstanding97.2491.8388.5585.5630.4012.4911.50
Earnings Per Share-0.07-0.69-0.70-1.54-3.67-6.46-6.73
Operating Cash Flow26.62-1.87-33.13-108-99.88-74.24-52.72
Capital Expenditures-10.49-6.71-7.37-17.66-10.27-2.32-3.63
Free Cash Flow16.14-8.58-40.50-125-110-76.56-56.34
Cash & Equivalents328248185220270103177
Total Debt16414997.3496.2323.10--
Net Cash / Debt16598.7488.10124246103177
Assets479340265282307118189
Liabilities26222815214056.5220.0017.13
Book Value21811211414225197.88172
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Novocure Limited
Country United Kingdom
Employees 782
CEO Asaf Danziger

Stock Information

Ticker Symbol NVCR
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: NVCR
IPO Date October 2, 2015

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.